• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

心房颤动继发卒中预防中直接使用新型口服抗凝药实用指南。

Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation.

作者信息

Sweis Rochelle, Biller José

机构信息

Department of Neurology, Stritch School of Medicine, Loyola University Chicago, Chicago, IL, USA.

出版信息

Curr Treat Options Cardiovasc Med. 2016 Apr;18(4):24. doi: 10.1007/s11936-016-0446-x.

DOI:10.1007/s11936-016-0446-x
PMID:26909818
Abstract

Anticoagulation remains the optimal treatment choice for secondary stroke prevention of AF. The vitamin K antagonists (VKAs) have been the choice of treatment for the last 60 years, but the new oral anticoagulants are now a safe option for treatment of non-valvular AF (NVAF) in the right patient population, taking into account age, renal function, bleeding risk, cardiovascular comorbidities, cost, and drug interactions.

摘要

抗凝治疗仍然是房颤继发性卒中预防的最佳治疗选择。在过去60年里，维生素K拮抗剂（VKAs）一直是治疗选择，但考虑到年龄、肾功能、出血风险、心血管合并症、成本和药物相互作用等因素，新型口服抗凝药现在对于合适的患者群体而言是治疗非瓣膜性房颤（NVAF）的安全选择。

相似文献

1
Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation.心房颤动继发卒中预防中直接使用新型口服抗凝药实用指南。
Curr Treat Options Cardiovasc Med. 2016 Apr;18(4):24. doi: 10.1007/s11936-016-0446-x.
2
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.更新的欧洲心脏节律协会实用指南：非维生素 K 拮抗剂抗凝剂在非瓣膜性心房颤动患者中的应用。
Europace. 2015 Oct;17(10):1467-507. doi: 10.1093/europace/euv309. Epub 2015 Aug 31.
3
Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.法国非瓣膜性心房颤动患者中阿哌沙班预防卒中和全身性栓塞：PAROS 横断面研究的原理和设计。
Arch Cardiovasc Dis. 2018 May;111(5):349-356. doi: 10.1016/j.acvd.2017.07.005. Epub 2017 Nov 27.
4
Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.处方正确吗？非瓣膜性心房颤动患者非维生素K拮抗剂抗凝剂（NOAC）处方的回顾。心房颤动安全处方及非维生素K口服抗凝剂在预防卒中中的评估（SAFE-NOACS）组。
Ir J Med Sci. 2019 Feb;188(1):101-108. doi: 10.1007/s11845-018-1837-7. Epub 2018 Jun 2.
5
Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.基于真实世界证据的非维生素 K 拮抗剂口服抗凝药与维生素 K 拮抗剂口服抗凝药用于非瓣膜性心房颤动患者卒中预防的治疗需要人数。
J Med Econ. 2019 Aug;22(8):760-765. doi: 10.1080/13696998.2019.1606001. Epub 2019 May 3.
6
EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.EHRA 实用指南：新型口服抗凝剂在非瓣膜性心房颤动患者中的应用：执行摘要。
Eur Heart J. 2013 Jul;34(27):2094-106. doi: 10.1093/eurheartj/eht134. Epub 2013 Apr 26.
7
Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.法国非瓣膜性心房颤动患者中阿哌沙班预防卒中和全身性栓塞：PAROS 横断面研究常规临床实践。
Arch Cardiovasc Dis. 2019 Jun-Jul;112(6-7):400-409. doi: 10.1016/j.acvd.2019.02.003. Epub 2019 Apr 20.
8
Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation.非瓣膜性心房颤动患者从维生素K拮抗剂转换为非维生素K拮抗剂的诸多充分理由。
J Clin Med. 2021 Jun 28;10(13):2866. doi: 10.3390/jcm10132866.
9
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.2018 年欧洲心脏病学会实用指南：非维生素 K 拮抗剂口服抗凝剂在心房颤动患者中的应用：执行摘要。
Europace. 2018 Aug 1;20(8):1231-1242. doi: 10.1093/europace/euy054.
10
Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.非维生素 K 拮抗剂口服抗凝剂和维生素 K 拮抗剂治疗的心房颤动患者的知识差异。
Kardiol Pol. 2018;76(7):1089-1096. doi: 10.5603/KP.a2018.0069. Epub 2018 Mar 12.

引用本文的文献

1
Reporting quality evaluation of the stroke clinical practice guidelines: a systematic review.报告质量评估的中风临床实践指南: 系统评价。
Syst Rev. 2021 Sep 30;10(1):262. doi: 10.1186/s13643-021-01805-3.

本文引用的文献

1
New oral anticoagulants: a practical guide for physicians.新型口服抗凝药物：医师实用指南。
Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):134-45. doi: 10.1093/ehjcvp/pvv002. Epub 2015 Feb 24.
2
Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.在一个基于人群的房颤患者队列中达比加群使用、安全性及有效性方面的性别差异
Circ Cardiovasc Qual Outcomes. 2015 Nov;8(6):593-9. doi: 10.1161/CIRCOUTCOMES.114.001398. Epub 2015 Oct 27.
3
Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants.
新型口服抗凝药的通用、类别特异性及药物特异性逆转剂。
J Thromb Thrombolysis. 2016 Feb;41(2):248-52. doi: 10.1007/s11239-015-1288-1.
4
New oral anticoagulants and neuraxial regional anesthesia.
Curr Opin Anaesthesiol. 2015 Oct;28(5):605-9. doi: 10.1097/ACO.0000000000000234.
5
How to Monitor Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Practice Tool Endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society.如何监测接受直接口服抗凝剂治疗以预防房颤中风的患者：加拿大血栓形成协会、加拿大中风联盟、加拿大心血管药剂师网络和加拿大心血管学会认可的实践工具
Ann Intern Med. 2015 Sep 1;163(5):382-5. doi: 10.7326/M15-0143.
6
Idarucizumab for Dabigatran Reversal.达比加群酯逆转剂依达鲁珠单抗。
N Engl J Med. 2015 Aug 6;373(6):511-20. doi: 10.1056/NEJMoa1502000. Epub 2015 Jun 22.
7
Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis.左心耳封堵术预防心房颤动患者卒中：一项基于患者的荟萃分析。
J Am Coll Cardiol. 2015 Jun 23;65(24):2614-2623. doi: 10.1016/j.jacc.2015.04.025.
8
Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study.大规模筛查未经治疗的心房颤动：STROKESTOP 研究。
Circulation. 2015 Jun 23;131(25):2176-84. doi: 10.1161/CIRCULATIONAHA.114.014343. Epub 2015 Apr 24.
9
Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.口服抗凝药预防心房颤动中的卒中：现状、特殊情况和未满足的需求。
Lancet. 2015 Jul 18;386(9990):303-10. doi: 10.1016/S0140-6736(15)60245-8. Epub 2015 Mar 14.
10
Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.评估新型口服抗凝剂在心房颤动卒中预防试验中疗效和安全性的网状Meta分析的批判性评价
Value Health. 2015 Mar;18(2):234-49. doi: 10.1016/j.jval.2014.10.012. Epub 2015 Jan 28.